Susquehanna International Group
NVCR icon

Susquehanna International Group’s NovoCure NVCR Stock Holding History

Susquehanna International Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.16M Buy
565,100
+42,500
+8% +$531K ﹤0.01% 3880
2025
Q4 		$6.76M Buy
522,600
+37,200
+8% +$478K ﹤0.01% 3578
2025
Q3 		$6.27M Buy
485,400
+164,800
+51% +$2.2M ﹤0.01% 3731
2025
Q2 		$5.71M Sell
320,600
-68,200
-18% -$1.19M ﹤0.01% 3732
2025
Q1 		$6.93M Sell
388,800
-7,900
-2% -$179K ﹤0.01% 3056
2024
Q4 		$11.8M Buy
396,700
+265,600
+203% +$5.62M ﹤0.01% 2454
2024
Q3 		$2.05M Sell
131,100
-7,900
-6% -$143K ﹤0.01% 5218
2024
Q2 		$2.38M Sell
139,000
-88,100
-39% -$1.55M ﹤0.01% 4745
2024
Q1 		$3.55M Sell
227,100
-4,600
-2% -$67.7K ﹤0.01% 4199
2023
Q4 		$3.46M Sell
231,700
-54,600
-19% -$731K ﹤0.01% 4333
2023
Q3 		$4.62M Sell
286,300
-31,400
-10% -$905K ﹤0.01% 3670
2023
Q2 		$13.2M Buy
317,700
+152,500
+92% +$9.47M ﹤0.01% 2166
2023
Q1 		$9.94M Buy
165,200
+12,800
+8% +$1.02M ﹤0.01% 2464
2022
Q4 		$11.2M Buy
152,400
+41,000
+37% +$3.08M ﹤0.01% 2135
2022
Q3 		$8.46M Sell
111,400
-43,900
-28% -$3.42M ﹤0.01% 2401
2022
Q2 		$10.8M Sell
155,300
-69,300
-31% -$5.22M ﹤0.01% 2113
2022
Q1 		$18.6M Sell
224,600
-35,000
-13% -$2.58M ﹤0.01% 1806
2021
Q4 		$19.5M Buy
259,600
+64,400
+33% +$6.46M ﹤0.01% 1878
2021
Q3 		$22.7M Sell
195,200
-30,400
-13% -$4.6M ﹤0.01% 1847
2021
Q2 		$50M Sell
225,600
-132,300
-37% -$25.7M 0.01% 1200
2021
Q1 		$47.3M Sell
357,900
-31,000
-8% -$4.9M 0.01% 1141
2020
Q4 		$67.3M Buy
388,900
+125,400
+48% +$17.2M 0.01% 853
2020
Q3 		$29.3M Buy
263,500
+35,300
+15% +$2.82M 0.01% 1185
2020
Q2 		$13.5M Sell
228,200
-115,800
-34% -$7.62M ﹤0.01% 1809
2020
Q1 		$23.2M Buy
344,000
+208,900
+155% +$16.5M 0.01% 1085
2019
Q4 		$11.4M Sell
135,100
-73,800
-35% -$5.96M ﹤0.01% 1952
2019
Q3 		$15.6M Buy
208,900
+95,900
+85% +$7.67M 0.01% 1535
2019
Q2 		$7.14M Sell
113,000
-225,100
-67% -$11.4M ﹤0.01% 2271
2019
Q1 		$16.3M Sell
338,100
-91,700
-21% -$4.41M 0.01% 1337
2018
Q4 		$14.4M Sell
429,800
-186,200
-30% -$6.81M 0.01% 1301
2018
Q3 		$32.3M Buy
616,000
+73,800
+14% +$2.94M 0.01% 964
2018
Q2 		$17M Sell
542,200
-207,900
-28% -$5.78M 0.01% 1427
2018
Q1 		$16.4M Sell
750,100
-69,900
-9% -$1.5M 0.01% 1375
2017
Q4 		$16.6M Sell
820,000
-37,200
-4% -$716K 0.01% 1401
2017
Q3 		$17M Buy
857,200
+343,800
+67% +$6.76M 0.01% 1344
2017
Q2 		$8.88M Sell
513,400
-71,500
-12% -$923K ﹤0.01% 1805
2017
Q1 		$4.74M Buy
584,900
+120,500
+26% +$870K ﹤0.01% 2422
2016
Q4 		$3.65M Buy
464,400
+348,100
+299% +$2.8M ﹤0.01% 2940
2016
Q3 		$993K Sell
116,300
-27,000
-19% -$246K ﹤0.01% 4812
2016
Q2 		$1.67M Buy
143,300
+51,800
+57% +$649K ﹤0.01% 3900
2016
Q1 		$1.32M Buy
91,500
+800
+0.9% +$11.5K ﹤0.01% 4520
2015
Q4 		$2.03M Buy
+90,700
New +$2.17M ﹤0.01% 4000

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Susquehanna International Group's NVCR Position: Q1 2026 in Review

Susquehanna International Group reduced its NovoCure (NVCR) stake by 3.3% in Q1 2026, selling an estimated $83.4K and leaving 197,375 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #6007.

Susquehanna International Group first reported a position in NVCR in Q1 2016 and has held it in 30 quarters since. The position peaked at $56M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Susquehanna International Group held 197,375 shares of NovoCure worth $2.15M as of Q1 2026.
  • Susquehanna International Group sold 6,678 NovoCure shares in Q1 2026, an estimated $83.4K.
  • NovoCure made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6007 holding.
  • Susquehanna International Group first reported a position in NovoCure in Q1 2016 and has held it in 30 quarters since.
  • Susquehanna International Group's NovoCure position peaked at $56M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.